Syncona Limited Freeline to present further FLT180a data at EAHAD
21 1월 2020 - 9:01PM
RNS Non-Regulatory
TIDMSYNC
Syncona Limited
21 January 2020
Freeline to present further FLT180a data at EAHAD
21 January 2020
Syncona announces that its portfolio company, Freeline will be
disclosing further data from its Phase 1/2 B-AMAZE trial
investigating a novel gene therapy, FLT180a, for Haemophilia B on
Friday 7 February 2020 at 14:00-15:00 at the 13th Annual Congress
of the European Association for Haemophilia and Allied Disorders
(EAHAD), The Hague, Netherlands. Syncona will provide the details
of this data via an RNS announcement. Previously, Freeline has
disclosed 66- and 74-week data for the first cohort of two patients
who were treated with the lowest study dose (4.5x1011vg/kg).
The Hot Topics session details have been published today and are
available on the EAHAD website at
https://eahadcongress.com/programme/programme/#friday.
Title: Phase 1/2 interim data from B-AMAZE study of adeno
associated virus (AAV) gene therapy (FLT180a) confirms progress
towards achieving Factor IX levels in the normal range for patients
with severe or moderately severe haemophilia B
Presenter: Dr Pratima Chowdary
Session Date and Time: Friday 7 February 2020 at 14:00 - 15:00
pm CET
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can
be found on the company website at: www.synconaltd.com
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Limited. These statements and forecasts
involve risk and uncertainty because they relate to events and
depend upon circumstances that may or may not occur in the future.
There are a number of factors that could cause actual results or
developments to differ materially from those expressed or implied
by these forward-looking statements. In particular, many companies
in the Syncona Limited portfolio are conducting scientific research
and clinical trials where the outcome is inherently uncertain and
there is significant risk of negative results or adverse events
arising. In addition, many companies in the Syncona Limited
portfolio have yet to commercialise a product and their ability to
do so may be affected by operational, commercial and other
risks.
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding a portfolio of global leaders in
life science. Our vision is to build a sustainable, diverse
portfolio of 15 - 20 companies focused on delivering
transformational treatments to patients in truly innovative areas
of healthcare, through which we are seeking to deliver strong
risk-adjusted returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We take
a long-term view, underpinned by a strategic capital base which
provides us with control and flexibility over the management of our
portfolio. We focus on delivering dramatic efficacy for patients in
areas of high unmet need.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFLFELLTILFII
(END) Dow Jones Newswires
January 21, 2020 07:01 ET (12:01 GMT)
Bacit (LSE:BACT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Bacit (LSE:BACT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024